Picture of TherapeuticsMD logo

TXMD TherapeuticsMD Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapNeutral

Momentum

Relative Strength (%)
1m-1.52%
3m-9.57%
6m-36.95%
1yr-51.61%
Volume Change (%)
10d/3m+6.62%
Price vs... (%)
52w High-51.53%
50d MA-1.17%
200d MA-22.34%

Growth & Value

12m Forecast RollingIndustryMarket
PE Ratio (f)6.54
PEG Ratio (f)n/a
EPS Growth (f)n/a
Dividend Yield (f)n/a
Valuation (ttm)IndustryMarket
Price to Book Value0.86
Price to Tang. Book1.13
Price to Free Cashflown/a
Price to Sales12.41
EV to EBITDA0.23

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital167.02%
Return on Equityn/a
Operating Margin3078.69%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202331st Dec 2024
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2023 / 2024

Blurred out image of TherapeuticsMD EPS forecast chart

Profile Summary

TherapeuticsMD, Inc. is a healthcare company. The Company is focused on developing and commercializing products exclusively for women. It is engaged in conducting business by out-licensing its products and collecting royalties, after granting a license to commercialize the Company's IMVEXXY, BIJUVA, and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands in the United States and its possessions and territories and assigning the Company’s exclusive license to commercialize ANNOVERA in the United States and its possessions and territories to Mayne Pharma. ANNOVERA is a one-year (13 cycles) ring-shaped contraceptive vaginal system (CVS)). ANNOVERA, which is made with a silicone elastomer, contains segesterone acetate, a 19-nor progesterone derivative also known as Nestorone (SA) and ethinyl estradiol (EE). Its menopause portfolio includes IMVEXXY and BIJUV. IMVEXXY (estradiol vaginal inserts) for the treatment of moderate-to-severe dyspareunia.

Directors

Last Annual
December 31st, 2022
Last Interim
September 30th, 2023
Incorporated
July 20th, 2010
Public Since
January 31st, 2001
No. of Shareholders
40,366
No. of Employees
1
Sector
Pharmaceuticals
Industry
Healthcare
Exchange
us flag iconNASDAQ Global Select Market
Shares in Issue
10,575,240

TXMD Share Price Performance

Upcoming Events for TXMD

Q4 2023 TherapeuticsMD Inc Earnings Release

Q1 2024 TherapeuticsMD Inc Earnings Release

TherapeuticsMD Inc Annual Shareholders Meeting

Q2 2024 TherapeuticsMD Inc Earnings Release

Similar to TXMD

Picture of Amgen logo

Amgen

us flag iconNASDAQ Global Select Market

Picture of Amphastar Pharmaceuticals logo

Amphastar Pharmaceuticals

us flag iconNASDAQ Global Select Market

Picture of Amylyx Pharmaceuticals logo

Amylyx Pharmaceuticals

us flag iconNASDAQ Global Select Market

Picture of Anika Therapeutics logo

Anika Therapeutics

us flag iconNASDAQ Global Select Market

Picture of Annexon logo

Annexon

us flag iconNASDAQ Global Select Market

FAQ